MedTrace Logo

Spanish Registry of Mohs Surgery

NCT02310503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2020-05-05

No results posted yet for this study

Summary

REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs surgery, and patient, tumor and technique factors related to adverse events and tumor recurrence.

REGESMOHS is a prospective cohort, including all patients considered for Mohs surgery in participating centers. All consecutive patients are included. The only exclusion criteria are being under 18-years-old or legally incompetent. Pre-planned follow-up is as required by common clinical practice, but at least once a year for the study period.

Conditions

  • Skin Neoplasms
  • Carcinoma, Basal Cell
  • Carcinoma, Squamous Cell
  • Dermatofibrosarcoma
  • Melanoma
  • Histiocytoma, Malignant Fibrous
  • Neoplasms, Adnexal and Skin Appendage

Interventions

PROCEDURE

Mohs surgery

A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Fundación Academia Española de Dermatología

    lead OTHER

Principal Investigators

  • Ignacio Garcia-Doval, MD, PhD · Research Unit. Academia Española de Dermatologia y Venereologia (Spanish Academy of Dermatology)

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-01
Primary Completion
2020-02-29
Completion
2020-02-29

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02310503 on ClinicalTrials.gov